Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis

Journal of Cellular Physiology

Volumn 183, Issue 1, 2000, Pages 1-9

  Grimberg, Adda ^a   Cohen, Pinchas ^b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MATTEL CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR;

APOPTOSIS; CANCER RISK; CARCINOGENESIS; COLORECTAL CANCER; GROWTH REGULATION; HUMAN; LUNG CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY MECHANISM; REVIEW;

ANIMALS; CELL DIVISION; COLORECTAL NEOPLASMS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; LUNG NEOPLASMS; MALE; NEOPLASMS; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1;

EID: 0034097566     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J     Document Type: Review

References (131)

1. Agarwal C, Lambert A, Chandraratna RA, Rorke EA, Eckert RL. 1999. Vitamin D regulates human ectocervical epithelial cell proliferation and insulin-like growth factor binding protein-3 level. Biol Reprod 60:567-572.
2. Andress DL, Birnbaum RS. 1992. Human osteoblast-derived insulin-like growth factor (IGF) binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF action. J Biol Chem 267:22467-22472.
3. Angelloz-Nicoud P, Binoux M. 1995. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology 136:5485-5492.
4. Angelloz-Nicoud P, Harel L, Binoux M. 1996. Recombinant human insulin-like growth factor (IGF) binding protein-3 stimulates prostate carcinoma cell proliferation via an IGF-dependent mechanism. Role of serine proteases. Growth Regul 6:130-136.
5. Arany E, Afford S, Strain AJ, Winwood PJ, Arthur MJ, Hill DJ. 1994. Differential cellular synthesis of insulin-like growth factor binding protein 1 and IGFBP-3 within human liver. J Clin Endocrinol Metab 79:1871-1876.
6. Baker J, Liu JP, Robertson EJ, Efstratiadis A. 1993. Role of insulin-like growth factors in embryonic and postnatl growth. Cell 75:73-82.
7. Ballard FJ, Knowles SE, Walton PE, Edson K, Owens PC, Mohler MA, Ferraiolo BL. 1991. Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I), IGF II and des(1-3)IGF-I in rats. J Endocrinol 128:197-204.
8. Barreca A, Artini PG, Cesarone A, Arvigo M, D'Ambrogio G, Genazzani AR, Giordano G, Minuto M. 1996. Interrelationships between follicle stimulating hormone and the growth hormone - insulin-like growth factor - IGF-binding proteins axes in human granulosa cells in culture. J Endocrinol Invest 19:35-42.
9. Barzilay J, Heatley GJ, Cushing GW. 1991. Benign and malignant tumors in patients with acromegaly. Arch Intern Med 151:1629-1632.
10. Baxter RC. 1994. Insulin-like growth factor binding proteins in the human circulation, a review. Horm Res 42:140-144.
11. Baxter RC, Daughaday WH. 1991. Impaired formation of the ternary insulin-like growth factor-binding protein complex in patients with hypoglycemia due to nonislet cell tumors. J Clin Endocrinol Metab 73:696-702.
12. Baxter RC, Saunders H. 1992. Radioimmunoassay of insulin-like growth factor-binding protein-6 in human serum and other body fluids. J Endocrinol 134:133-139.
13. Blakesley VA, Koval AP, Stannard BS, Scrimgeour A, LeRoith D. 1998. Replacement of tyrosine 1251 in the carboxyl terminus of the insulin-like growth factor-I receptor disrupts the actin cytoskeleton and inhibits proliferation and anchorage-independent growth. J Biol Chem 273:18411-18422.
14. Blat C, Villaudy J, Binoux M. 1994. In vivo proteolysis of serum IGFBP-3 results in increased availability of IGF to target cells. J Clin Invest 93:2286-2290.
15. Booth BA, Boes M, Dake BL, Bar RS. 1999. Isolation and characterization of plasmin-generated bioactive fragments of IGFBP-3. Am J Physiol 276:E450-454.
16. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, Kley N. 1995. Induction of the growth inhibitor IGF-binding protein-3 by p53. Nature 377:646-649.
17. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollack M. 1998. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279:563-566.
18. Chen H, Van GC, Gishizky ML. 1998. Identification of structural characteristics that contribute to a difference in antiapoptotic function between human insulin and insulin-like growth factor-I receptors. Cell Growth Differ 9:939-947.
19. Chin E, Zhou J, Dai J, Baxter RC, Bondy CA. 1994. Cellular localization of gene expression for components of the IGF ternary complex. Endocrinology 134:2498-2504.
20. Clemmons DR, Cascieri MA, Camacho-Hubner C, McCusker RH, Bayne ML. 1990. Discrete alterations of the IGF-I molecule which alter its affinity for IGF binding proteins result in changes in bioactivity. J Biol Chem 265:12210-12216.
21. Cohen P. 1998. Serum insulin-like growth factor-I levels and prostate cancer risk - interpreting the evidence. J Natl Cancer Inst 90:876-878.
22. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. 1992. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 75:1046-1053.
23. Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, Rosenfeld RG. 1993a. Elevated levels of insulin-like growth factor binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 76:1031-1035.
24. Cohen P, Lamson G, Okajima T, Rosenfeld RG. 1993b. Transfection of the human insulin-like growth factor binding protein-3 gene into Balb/c fibroblasts inhibits cellular growth. Mol Endocrinol 7:380-386.
25. Cohen P, Peehl DM, Graves HC, Rosenfeld RG. 1994. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 142:407-415.
26. Cohen P, Rosenfeld RG. 1995. The IGF axis. In: Rosenbloom AL, editor. Human growth hormone, basic and scientific aspects. Boca Raton, FL: CRC Press. p 43-58.
27. Colao A, Marzullo P, Speza S, Ferone D, Giaccio A, Cerbone G, Pivonello R, di Somma C, Lombardi G. 1999. Effect of growth hormone (GH) and of insulin-like growth factor I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH deficiency, and healthy subjects. J Clin Endocrinol Metab 84:1986-1991.
28. Conover CA, Clarkson JT, Durham SK, Bale LK. 1993. Cellular actions of insulin-like growth factor binding protein-3. In: LeRoith D, Raizada MK, editors. Current directions in insulin-like growth factor research. New York: Plenum Press. p 255-265.
29. Conover C, DeLeon DD. 1994b. Acid activated insulin-like growth factor binding protein-3 proteolysis in normal and transformed cells. Role of cathepsin D. J Biol Chem 2691:7076-7080.
30. Conover C, Perry J, Tindall D. 1995. Endogenous cathepsin-D-mediated hydrolysis of insulin-like growth factor-binding proteins in cultured human prostatic carcinoma cells. J Clin Endocrinol Metab 80:987-993.
31. Conover CA, Powell DR. 1991. Insulin-like growth factor (IGF)-binding protein-3 blocks IGF-I-induced receptor down-regulation and cell desensitization in cultured bovine fibroblasts. Endocrinology 129:710-716.
32. D'Ambrosio C, Ferber A, Resnicoff M, Baserga R. 1996. A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res 56:4013-4020.
33. D'Ambrosio C, Valentinis B, Prisco M, Reiss K, Rubini M, Baserga R. 1997. Protective effect of the insulin-like growth factor I receptor on apoptosis induced by okadaic acid. Cancer Res 57:3264-3271.
34. DeMellow JSM, Baxter RC. 1988. Growth hormone-dependent insulin-like growth factor (IGF) binding protein both inhibits and potentiates IGF-I stimulated DNA synthesis in human skin fibroblasts. Biochem Biophys Res Commun 156:199-204.
35. Dews M, Nishimoto I, Baserga R. 1997. IGF-I receptor protection from apoptosis in cells lacking the IRS proteins. Recept Signal Transduc 7:231-240.
36. Doglio A, Dani C, Fredrikson G, Grimaldi P, Ailhaud G. 1987. Acute regulation of insulin-like growth factor-I gene expression by growth hormone during adipose cell differentiation. EMBO J 6:4011-4016.
37. Donnelly MJ, Holly JM. 1996. The role of IGFBP-3 in the regulation of IGFBP-4 proteolysis. J Endocrinol 149:R1-R7.
38. Dunn SE, kari FW, Franch J, Leininger JR, Travlos G, Wilson R, Barrett JC. 1997. Dietary restriction reduces insulin-like growth factor-I levels, which modulates apoptosis, cell proliferation and tumor progression in p53-deficient mice. Cancer Res 57:4667-672.
39. Durham SK, Suwanichkul A, Hayes JD, Herington AC, Powell DR, Campbell PG. 1999. The heparin-binding domain of insulin-like growth factor binding protein (IGFBP)-3 increases susceptibility of IGFBP-3 to proteolysis. Horm Metab Res 31:216-225.
40. Edmondson SR, Murashita MM, Russo VC, Wraight CJ, Werther GA. 1999. Expression of insulin-like growth factor binding protein-3 (IGFBP-3) in human keratinocytes is regulated by EGF and TGF-beta1. J Cell Physiol 179:201-207.
41. Elis MJ, Leav BA, Yang Z, Rasmussen A, Pearce A, Zweibel JA, Lippman ME, Cullen KJ. 1996. Affinity for insulin-like growth factor-II (IGF-II) receptor inhibits autocrine IGF-II activity in MCF-7 breast cancer cells. Molec Endocrinol 10:286-297.
42. Erickson GF, Kubo T, Li D, Kim H, Shimasaki S. 1998. The IGF system in the ovary. In: Takano K, Hizuka N, Takahashi S-I, editors. Molecular mechanisms to regulate the activities of insulin-like growth factors. Amsterdam: Elsevier Science B.V. p 185-193.
43. Erondu NE, Dake BL, Moser DR, Lin M, Boes M, Bar RS. 1996. Regulation of endothelial IGFBP-3 synthesis and secretion by IGF-I and TGF-beta. Growth Regul 6:1-9.
44. Erondu NE, Nwankwo J, Zhong Y, Boes M, Dake B, Bar RS. 1999. Transcriptional and posttranscriptional regulation of insulin-like growth factor binding protein-3 by cyclic adenosine 3′,5′-monophosphate: messenger RNA stabilization is accompanied by decreased binding of a 42-kDa protein to a uridine-rich domain in the 3′-untranslated region. Mol Endocrinol 13:495-504.
45. Esposito DL, Blakelsey VA, Koval AP, Scrimgeour AG, LeRoith D. 1997. Tyrosine residues in the C-terminal domain of the insulin-like growth factor-I receptor mediate mitogenic and tumorigenic signals. Endocrinology 138:979-2988.
46. Ezzat S, Melmed S. 1991. Clinical review 18: are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol Metab 72:245-249.
47. Ferry RJ Jr, Katz LE, Grimberg A, Cohen P, Weinzimer SA. 1999. Cellular actions of insulin-like growth factor-binding proteins. Horm Metab Res 31:192-202.
48. Fowlkes JL, Enghild JJ, Suzuki K, Nagase H. 1994a. Matrix metalloproteinases degrade insulin-like growth factor binding protein-3 in dermal fibroblast cultures. J Biol Chem 269:742-746.
49. Fowlkes JL, Suzuki K, Nagase H, Thrailkill KM. 1994b. Proteolysis of insulin-like growth factor binding protein-3 during rat pregnancy: a role for matrix metalloproteinases. Endocrinology 135:2810-2813.
50. Fowlkes JL, Thrailkill KM, George-Nascimento C, Rosenberg CK, Serra DM. 1997. Heparin-binding, highly basic regions within the thyroglobulin type-1 repeat of insulin-like growth factor (IGF)-binding proteins (IGFBPs) -3, -5, and -6 inhibit IGFBP-4 degradation. Endocrinology 138:2280-2285.
51. Friedlander P, Haupt Y, Prives C, Oren M. 1996. A mutant p53 gene that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol 16:4961-4971.
52. Grimberg A, Cohen P. 1999. Growth hormone and prostate cancer: guilty by association? J Endocrinol Invest 22:64-73.
53. st Annual Meeting of The Endocrine Society (San Diego CA). Bethesda, MD: The Endocrine Society. p 167.
54. Grimberg A, Rajah R, Zhao H, Cohen P. 1998. The prostatic IGF system: new levels of complexity. In: Takano K, Hizuka N, Takahashi S-I, editors. Molecular mechanisms to regulate the activities of insulin-like growth factors. Amsterdam: Elsevier Science B.V. p 205-213.
55. Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG. 1996. Insulin-like growth factor binding protein 3 mediaties retinoic acid-and transforming growth factor β2-induced growth inhibition in human breast cancer cells. Cancer Res 56:1545-1550.
56. Guler HP, Zapf J, Schmid C, Froesch ER. 1989. Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol 121:753-758.
57. Han GR, Dohi DF, Lee HY, Rajah R, Walsh GL, Hong WK, Cohen P, Kurie JM. 1997. All-trans-retinoic acid increases transforming growth factor-beta2 and insulin-like growth factor binding protein-3 expression through a retinoic acid receptor-alpha-dependent signaling pathway. J Biol Chem 272:13711-13716.
58. Ho PJ, Baxter RC. 1997. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol 46:333-342.
59. Hodgkinson S, Fowke P, Al Somai N, McQuoid M. 1995. Proteins in tissue extracts which bind insulin-like growth factor binding protein-3 (IGFBP-3). J Endocrinol 145:R1-R6.
60. Hongo A, D'Ambrosio C, Miura M, Morrione A, Baserga R. 1996. Mutational analysis of the mitogenic and transforming activities of the insulin-like growth factor I receptor. Oncogene 12:1231-1238.
61. Huynh H, Yang YF, Pollak M. 1996. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 271:1016-1021.
62. Jaques G, Noll K, Wegmann B, Witten S, Kogan E, Radulescu RT, Havemann K. 1997. Nuclear localization of insulin-like growth factor binding protein 3 in a lung cancer cell line. Endocrinology 138:1767-1770.
63. Jones JI, Gockerman A, Busby WH Jr, Camacho-Hubner C, Clemmons DR. 1993. Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I. J Cell Biol 121:679-687.
64. Kajimoto Y, Umayahara Y, Fujitani Y, Yamasaki Y, Hori M. 1998. Involvement of AP-1-like motifs in the IGF-I gene regulation. In: Takano K, Hizuka N, Takahashi S-I, editors. Molecular mechanisms to regulate the activities of insulin-like growth factors. Amsterdam: Elsevier Science B.V. p 31-38.
65. Kamai Y, Mikawa S, Endo K, Sakai H, Komano T. 1996. Regulation of insulin-like growth factor-I expression in mouse preadipocyte Ob1771 cells. J Biol Chem 271:9883-9886.
66. Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldwasser B, Karasik A. 1993. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 77:229-233.
67. Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM. 1999. The insulin-like growth factor axis and prostate cancer: lessons learned from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 59:2203-2209.
68. Karas M, Danilenko M, Fishman D, LeRoith D, Levy J, Sharoni Y. 1997. Membrane-associated insulin-like growth factor-binding protein-3 inhibits insulin-like growth factor-I-induced insulin-like growth factor-I receptor signaling in ishikawa endometrial cancer cells. J Biol Chem 272:16514-16520.
69. Kassem M, Okazaki R, Harris SA, Spelsberg TC, Conover CA, Riggs BL. 1998. Estrogen effects on of insulin-like growth factor gene expression in a human osteoblastic cell line with high levels of estrogen receptor. Calcif Tissue Int 62:60-66.
70. Klein I, Parveen G, Gavoeler JS, Vanthiel DH. 1982. Colonie polyps in patients with acromegaly. Ann Intern Med 97:27-30.
71. Koistinen R, Itkonen P, Selenius P, Seppala M. 1990. Insulin-like growth factor binding protein-1 inhibits binding of IGF-I on fetal skin fibroblasts but stimulates their DNA synthesis. Biochem Biophys Res Commun 173:408-415.
72. Ladas SD, Thalassinos NC, Toannides G, Raptis SA. 1994. Does acromegaly really predispose to an increased prevalence of gastrointestinal tumours? Clin Endocrinol (Oxf) 41:597-601.
73. Lalou C, Lassarre C, Binoux M. 1996. A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology 137:3206-3212.
74. Landis SH, Murray T, Bolden S, Wingo PA. 1998. Cancer statistics, 1998. CA Cancer J Clin 48:6-29.
75. Leal SM, Liu Q, Huang SS, Huang JS. 1997. The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein-3 receptor. J Biol Chem 272:20572-20576.
76. LeRoith D, Koval AP, Butler AA, Yakar S, Karas M, Stannard BS, Blakesley VA. 1998. The insulin-like growth factor-I receptor and cellular signaling: implications for celular proliferation and tumorigenesis. In: Takano K, Hizuka N, Takahashi S-I, editors. Molecular mechanisms to regulate the activities of insulin-like growth factors. Amsterdam: Elsevier Science B.V. p 285-290.
77. Li YM, Schacher DH, Liu Q, Arkins S, Rebeiz N, McCusker RH Jr, Dantzer R, Kelley KW. 1997. Regulation of myeloid growth and differentiation by the insulin-like growth factor I receptor. Endocrinology 138:362-368.
78. st Annual Meeting of The Endocrine Society (San Diego CA). Bethesda, MD: The Endocrine Society. p A-49.
79. st Annual Meeting of The Endocrine Society (San Diego CA). Bethesda, MD: The Endocrine Society, p 405.
80. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. 1993. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-I) and type 1 IGF receptor (Igf1r). Cell 75:59-72.
81. Lowe WL Jr, Adamo M, Werner H, Roberts CT, Jr, LeRoith D. 1989. Regulation by fasting of rat insulin-like growth factor-I and its receptor: effects on gene expression and binding. J Clin Invest 84:619-626.
82. Ludwig RL, Bates S, Vousden KH. 1996. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Bio 16:4952-4960.
83. Ludwig T, Eggenschweiler J, Fisher P, D'ercole AJ, Davenport ML, Efstratiadis A. 1996. Mouse mutants lacking the type 2 IGF receptor (IGF2R) are resuced from perinatal lethality in Igf2 and Igf1r null backgrounds. Dev Biol 177:517-535.
84. Ma J, Pollack MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ. 1999. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91:620-625.
85. MacDonald RG, Schaffer BS, Kang IJ, Hong SM, Kim EJ, Park JH. 1999. Growth inhibition and differentiation of the human colon carcinoma cell line, Caco-2, by constitutive expression of insulin-like growth factor binding protein-3. J Gastroenterol Hepatol 14: 72-78.
86. Mannhardt B, Weinzimer SA, Cohen P, Jansen-Durr P, Zwerschke W. 1999. The human papillomavirus E7 oncoprotein binds and inactivates the growth inhibitory IGF-binding protein-3. Nat Cell Biol (submitted).
87. Mantzoros CS, Tzonou A, Signorello LB, Stampfer A, Trichopoulos D, Adami HO. 1997. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 76:1115-1118.
88. McCarthy TL, Centrella M, Canalis E. 1990. Cyclic AMP induces insulin-like growth factor 1synthesis in osteoblast-enriched cultures. J Biol Chem 265:15353-15356.
89. Neumann GM, Bach LA. 1999. The N-terminal disulfide linkages of human insulin-like growth factor-binding protein-6 (hIGFBP-6) and hIGFBP-1 are different as determined by mass spectrometry. J Biol Chem 274:14587-14594.
90. th International Symposium on Insulin-like Growth Factors (Tokyo, Japan). Foundation for Growth Science, p 139.
91. Nunn S, Peehl DM, Cohen P. 1997. Acid-activated insulin-like growth factor binding protein protease activity of cathepsin D in normal and malignant prostatic epithelial cells and seminal plasma. J Cell Physiol 171:196-204.
92. O'Connor R, Kauffmann-Zeh A, Liu Y, Lehar S, Evan GI, Baserga R, Blattler WA. 1997. Identification of domains of the insulin-like growth factor-I receptor that are required for protection from apoptosis. Mol Cell Biol 17:427-435.
93. Oh Y, Müller HL, Pham H, Rosenfeld RG. 1993a. Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J Biol Chem 268:26045-26048.
94. Oh Y, Müller HL, Lamson G, Rosenfeld RG. 1993b. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem 268:14964-14971.
95. Okabe E, Kajihara J, Usami Y, Hirano K. 1999. The cleavage site specificity of human prostate specific antigen for insulin-like growth factor binding protein-3. FEBS Lett 19:87-90.
96. Okazaki R, Durham SK, Riggs BL, Conover CA. 1995. Transforming growth factor-beta and forskolin increase all classes of insulin-like growth factor-I transcripts in normal human osteoblast-like cells. Biochem Biophys Res Commun 207:963-970.
97. Olivecrona H, Hilding A, Ekstrom C, Barle H, Nyberg B, Moller C, Delhanty PJ, Baxter RC, Angelin B, Ekstrom TJ, Tally M. 1999. Acute and short-term effects of growth hormone on insulin-like growth factors and their binding proteins: serum levels and hepatic messenger ribonucleic acid responses in humans. J Clin Endocrinol Metab 84:553-560.
98. Olney RC, Tsuchiya K, Wilson DM, Mohtai M, Maloney WJ, Schurman DJ, Smith RL. 1996. Chondrocytes from osteoarthritic cartilage have increased expression of insulin-like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3) and -5, but not IGF-II or IGFBP-4. J Clin Endocrinol Metab 81:1096-1103.
99. Parisot JP, Hu XF, DeLuise M, Zalcberg JR. 1999. Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line. Br J Cancer 79:693-700.
100. Prisco M, Hongo A, Rizzo MG, Sacchi A, Baserga R. 1997. The insulin-like growth factor I receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin-3 withdrawal. Molec Cell Biol 17:1084-1092.
101. Rajah R, Bhala A, Nunn SE, Peehl DM, Cohen P. 1996a. 7S nerve growth factor is an insulin-like growth factor binding protein protease. Endocrinology 137:2676-2682.
102. Rajah R, Katz L, Nunn S, Solberg P, Beers T, Cohen P. 1996b. Insulin-like growth factor binding protein proteases: functional regulators of cell growth. Prog Growth Factor Res 6:273-284.
103. Rajah R, Valentis B, Cohen P. 1997. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death via a p53-and IGF-independent mechanism. J Biol Chem 272:12181-12188.
104. Resnicoff M, Abraham D, Yutanawioonchai W, Rotman HL, Kajstura J, Rubin R, Zoltick P, Baserga R. 1995. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 55:2463-2469.
105. Rinderknecht E, Humbel RE. 1978a. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 253:2769-2776.
106. Rinderknecht E, Humbel RE. 1978b. Primary structure of human insulin-like growth factor II. FEBS Lett 89: 283-286.
107. Ron E, Gridley G, Hrubec Z, Page W, Arora S, Fraumeni JF Jr. 1991. Acromegaly and gastrointestinal cancer. Cancer 68:1673-1677. [erratum in Cancer 69:549, 1992].
108. Rotwein P. 1991. Structure, evolution, expression and regulation of insulin-like growth factors I and II. Growth Factors 5:3-18.
109. Salahifar H, Baxter RC, Martin JL. 1997. Insulin-like growth factor binding protein (IGFBP)-3 protease activity secreted by MCF-7 breast cancer cells: inhibition by IGFs does not require IGF-IGFBP interaction. Endocrinology 138:1683-1690.
110. Schedlich LJ, Young TF, Firth SM, Baxter RC. 1998. Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. J Biol Chem 273:18347-18352.
111. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. 1993. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type I insulin-like growth factor receptor. Proc Natl Acad Scien USA 90:11217-11221.
112. Shang Y, Baumrucker CR, Green MH. 1999. Signal relay by retinoic acid receptors alpha and beta in the retinoic acid-induced expression of insulin-like growth factor-binding protein-3 in breast cancer cells. J Biol Chem 18:18005-18010.
113. Shen L, Dean NM, Glazer RI. 1999. Induction of p53-dependent, insulin-like growth factor-binding protein-3-mediated apoptosis in glioblastoma mutliforme cells by a protein kinase Cα antisense oligonucleotide. Molec Pharmacol 55:396-402.
114. Stoving RK, Flyvbjerg A, Frystyk J, Fisker S, Hangaard J, Hansen-Nord M, Hagen C. 1999. Low serum levels of free and total insulin-like growth factor I (IGF-I) in patients with anorexia nervosa are not associated with increased IGF-binding protein-3 proteolysis. J Clin Endocrinol Metab 84:1346-1350.
115. Strauss DS, Takemoto CD. 1990. Effect of dietary protein deprivation on insulin-like growth factor (IGF)-I and -II, IGF binding protein-2, and serum albumin gene expression in rat. Endcorinol 127:1849-1860.
116. Strauss DS, Takemoto CD. 1991. Specific decrease in liver insulin-like growth factor-I and brain insulin-like growth factor-II gene expression in energy-restricted rats. J Nutrit 121:1279-1286.
117. Swolin D, Brantsing C, Matejka G, Ohlsson C. 1996. Cortisol decreases IGF-I mRNA levels in human osteoblast-like cells. J Endocrinol 149:397-403.
118. Troisi RJ, Freedman AN, Devesa SS. 1999. Incidence of colorectal carcinoma in the U.S.: an update of trends by gender, race, age, subsite, and stage, 1975-1994. Cancer 85:1670-1676.
119. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chen E, et al. 1986. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 5:2503-2512.
120. Valentinis B, Bhala A, DeAngelis T, Baserga R, Cohen P. 1995. The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol Endocrinol 9:361-367.
121. st Annual Meeting of The Endocrine Society (San Diego CA). Bethesda, MD: The Endocrine Society, p 83.
122. Wingo PA, Ries LA, Giovino GA, Miller DS, Rosenberg HM, Shopland DR, Thun MJ, Edwards BK. 1999. Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst 91:675-690.
123. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D. 1998. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 90:911-915.
124. th International Symposium on Insulin-like Growth Factors (Tokyo, Japan). Foundation for Growth Science (Tokyo, Japan). p 139.
125. Wraight CJ, Liepe IJ, White PJ, Hibbs AR, Werther GA. 1998. Intranuclear localization of insulin-like growth factor binding protein-3 (IGFBP-3) during cell division in human keratinocytes. J Invest Dermatol 111:239-242.
126. th Annual Meeting of The Endocrine Society (New Orleans LA). Bethesda, MD: The Endocrine Society. p 313.
127. Yamanaka Y, Fowlkes JL, Wilson EM, Rosenfeld RG, Oh Y. 1999. Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. Endocrinology 140:1319-1328.
128. Yang YW-H, Yanagishita M, Rechler MM. 1996. Heparin inhibition of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human fibroblasts and rat glioma cells: role of heparan sulfate proteoglycans. Endocrinology 137:4363-4371.
129. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. 1999. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91:151-156.
130. Zadeh SM, Binoux M. 1997. The 16-kDa proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 inhibits the mitogenic action of fibroblast growth factor on mouse fibroblasts with a targeted disruption of the type 1 IGF receptor gene. Endocrinology 138:3069-3072.
131. Zheng B, Clarke JB, Busby WH, Duan C, Clemmons DR. 1998. Insulin-like growth factor-binding protein-5 is cleaved by physiological concentrations of thrombin. Endocrinology 139:1708-1714.